Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-001 - Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial
09:30 - 09:30 | Presenter: D. Ross Camidge | Author(s): M. Tiseo, Myung-Ju Ahn, Karen L Reckamp, K.H. Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, H.J. Groen, Maximilian Johannes Hochmair, Natasha B Leighl, Scott N. Gettinger, Corey J Langer, Luis Paz-Ares, Egbert F Smit, E.S. Kim, W. Reichmann, D. Kerstein, D. Kim
- Abstract
Loading... -
+
P1.01-004 - Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC
09:30 - 09:30 | Presenter: D. Ross Camidge | Author(s): Myung-Ju Ahn, Karen L Reckamp, Howard L West, Rudolf M Huber, Corey J Langer, Lyudmila A Bazhenova, Natasha B Leighl, W. Reichmann, D. Kerstein, D. Kim
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.11 - A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
12:10 - 12:15 | Presenter: Jonathan W Riess | Author(s): Karen L Reckamp, J. Longmate, Karen Kelly, David R. Gandara, Philip Christopher Mack, E. Newman, Primo Lara
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.05 - Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
16:30 - 16:40 | Presenter: Myung-Ju Ahn | Author(s): D. Ross Camidge, M. Tiseo, Karen L Reckamp, K.H. Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, H.J. Groen, Maximilian Johannes Hochmair, Natasha B Leighl, Scott N. Gettinger, Corey J Langer, Luis Paz-Ares, Egbert F Smit, E.S. Kim, W. Reichmann, D. Kerstein, D. Kim
- Abstract
Loading...
-
+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P2.03-043 - A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Sukhmani Kaur Padda | Author(s): Karen L Reckamp, M. Koczywas, Joel W. Neal, J. Kawashima, S. Kong, Y. Xin, D. Huang, Heather A Wakelee
- Abstract
Loading... -
+
P2.03-058 - Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: James Chih-Hsin Yang | Author(s): Karen L Reckamp, Young-Chul Kim, Silvia Novello, Egbert F Smit, J. Lee, W. Su, W.L. Akerley, C. Blakely, Lyudmila A Bazhenova, R. Chiari, T. Hsia, T. Golsorkhi, D. Despain, D. Shih, L. Rolfe, Sanjay Popat, Heather A Wakelee
- Abstract
Loading...
-
+
OA 08 - Neuroendocrine Carcinoma: Translational
- 11:00 - 12:30
- 10/17/2017
- Location: Room 311 + 312
- Type: Oral
- Track: SCLC/Neuroendocrine Tumors
- Moderators:David S Ettinger, S. Zöchbauer-Müller
-
+
OA 08.08 - Discussant - OA 08.05, OA 08.06, OA 08.07
12:15 - 12:30 | Presenter: Karen L Reckamp
- Abstract
No abstract available for this presentation